Docetaxel in advanced non-small cell lung cancer

Expert Review of Anticancer Therapy

Volumn 5, Issue 1, 2005, Pages 13-24

  Wakelee, Heather ^a   Ramalingam, Sakkaraiappan ^b   Belani, Chandra P ^b  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Docetaxel; Non small cell lung cancer; Taxanes

Indexed keywords

ANTIBODY CONJUGATE; BEVACIZUMAB; BEXAROTENE; BORTEZOMIB; CANFOSFAMIDE; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ENOXAPARIN; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; GEMCITABINE; GLUTATHIONE DERIVATIVE; IFOSFAMIDE; IRINOTECAN; KETOCONAZOLE; NAVELBINE; OBLIMERSEN; PACLITAXEL; PEMETREXED; PIVALOYLOXYMETHYL BUTYRATE; SGN 15; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINDESINE;

ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; CONJUNCTIVITIS; DIARRHEA; DISEASE SEVERITY; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; DYSPNEA; ELDERLY CARE; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; PAIN; PERIPHERAL EDEMA; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SKIN DISEASE; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 14244255859     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.1.13     Document Type: Review

References (98)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin. 54(1), 8-29 (2004).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94(2), 153-156 (2001 ).
3. Ettinger DS, Cox JD, Ginsberg RJ et al. NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 10(Suppl. 11), 81-111 (1996).
4. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J. Clin. Oncol. 14(2), 671-679 (1996).
5. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl Cancer Inst. 83(4), 288-291 (1991).
6. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55(1), 5-30 (1998).
7. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17(3), 1061-1070 (1999).
8. Guidolin D, Vacca A, Nussdorfer GG, Ribatti D. A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc. Res. 67(2), 117-124 (2004).
9. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of anti-angiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer 104(1), 121-129 (2003).
10. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat. Rev. 29(5), 407-415 (2003).
11. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976 NSC 628503) given as a short intravenous infusion. Cancer Res. 53(5), 1037-1042 (1993).
12. Engels FK, Ten Tije AJ, Baker SD et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol. Ther. 75(5), 448-454 (2004).
13. Synold T, Newman E, Lenz H-J et al. Prospective evaluation of docetaxel (D) pharmacokinetics (PK) and toxicity in patients with tumor-related hepatic dysfunction (HD). Proc. Am. Soc. Clin. Oncol. 18, 168a (1999) (Abstract 643).
14. Pronk LC, Schellens JH, Planting AS et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J. Clin. Oncol. 15(3), 1071-1079 (1997).
15. Millward MJ, Zalcberg J, Bishop JF et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 15(2), 750-758 (1997).
16. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese co-operative study. J. Clin. Oncol. 14(5), 1649-1655 (1996).
17. Cerny T, Kaplan S, Pavlidis N et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a Phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer 70(2), 384-387 (1994).
18. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75(4), 968-972 (1995).
19. Latreille J, Gelmon KA, Hirsh V et al. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest. New Drugs 16(3), 265-270 (1998).
20. Fossella FV, Lee JS, Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol. 12(6), 1238-1244 (1994).
21. Francis PA, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with Stage III and IV non-small-cell lung cancer. J. Clin. Oncol. 12(6), 1232-1237 (1994).
22. Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27(3), 145-157 (2000).
23. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 22(2), 330-353 (2004).
24. Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18(12), 2354-2362 (2000).
25. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095-2103 (2000).
26. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized Phase III trial. Lung Cancer 43(2), 183-194 (2004).
27. Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004).
28. Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol. 16(6), 2164-2168 (1998).
29. Lilenbaum RC, Schwartz MA, Seigel L et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 92(8), 2158-2163 (2001).
30. Ardizzoia A, Acquati M, Fagnani D et al. Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian Phase II study. Lung 182(1), 1-8 (2004).
31. Esteban E, Gonzalez de Sande L, Fernandez Y et al. Prospective randomised Phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann. Oncol. 14(11), 1640-1647 (2003).
32. Petrioli R, Pozzessere D, Messinese S et al. Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer 39(1), 85-89 (2003).
33. Serke M, Schoenfeld N, Loddenkemper R. Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial. Anticancer Res. 24(2C), 1211-1216 (2004).
34. Rossi D, Graziano F, Ugolini M et al. Weekly docetaxel as second-line therapy in non-small cell lung cancer: a Phase II study. Tumori 90(1), 50-53 (2004).
35. Vazquez S, Grande C, Amenedo M et al. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a Phase II study of the Galician Lung Cancer Group (GGCP 006-00). Anticancer Drugs 15(5), 489-494 (2004).
36. Chen Y-M, Shih J-F, Tsai C-M, Perng R-P, Whang-Peng J. Preliminary report of a randomized trial of different docetaxel schedules in non-small cell lung cancer patients failing previous chemotherapy. J. Clin. Oncol. 22(Suppl. 14), 644s (2004) (Abstract 7112).
37. Gridelli C, Illiano A, Salvagni S et al. Effect on quality-of-life (QoL) of weekly vs. 3-weekly docetaxel (D) in second-line treatment of advanced non-small-cell lung cancer. The DISTAL randomized Phase 3 study. Proc. Am. Soc. Clin. Oncol. 22, 625 (2003) (Abstract 2515).
38. Camps C, Massuti B, Jimenez AM et al. Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) Phase III trial. Proc. Am. Soc. Clin. Oncol. 22, 625 (2003) (Abstract 2514).
39. Schuette W, Nagel S, Serke M, Lautenschlaeger C, Hans K, Lorenz C. Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: results of a randomized Phase III study. J. Clin. Oncol. 22(Suppl. 14), 625s (2004) (Abstract 7036).
40. Georgoulias V, Ardavanis A, Agelidou A et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter Phase III trial. J. Clin. Oncol. 22(13), 2602-2609 (2004).
41. Groen H, Schramel FM, Van der Hoeven JJM et al. Docetaxel and carboplatin once every 3 week versus weekly docetaxel in advanced non-small cell lung cancer (NSCLC). An interim analysis of a multicenter Phase III trial. Proc. Am. Soc. Clin. Oncol. 22, 623 (2003) (Abstract 2505).
42. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
43. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 21(16), 3016-3024 (2003).
44. Kubota Y, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with Stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J. Clin. Oncol. 22(2), 254-261 (2004).
45. Ramalingam S, Dobbs TW, Einzig AI et al. Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter Phase II study. Cancer Chemother. Pharmacol. 53(5), 439-444 (2004).
46. Millward MJ, Boyer MJ, Lehnert M et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a Phase II study in Caucasian and Asian patients. Ann. Oncol. 14(3), 449-454 (2003).
47. Giannakakis T, Kakolyris S, Theodoropoulos E et al. A multicenter Phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Anticancer Res. 22(6B), 3743-3748 (2002).
48. Jahanzeb M, Sarna G, Hirsch R et al. Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a Phase II study. Anticancer Res. 24(2C), 1239-1242 (2004).
49. Lorigan P, Booton R, Ashcroft L et al. Randomised Phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) - final results of a British Thoracic Oncology Group (BTOG) trial. J. Clin. Oncol. 22(Suppl. 14), 632s (2004) (Abstract 7066).
50. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357(9267), 1478-1484 (2001).
51. Popa IE, Stewart K, Smith FP, Rizvi NA. A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer 95(8), 1714-1719 (2002).
52. Israel V, Tagawa ST, Snyder T, Jeffers S, Raghavan D. Phase I/II trial of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC). Invest. New Drugs 22(3), 291-297 (2004).
53. Rocha Lima CM, Rizvi NA, Zhang C et al. Randomized Phase II trial of gemcitabine plus irinotecan or docetaxel in Stage IIIB or Stage IV NSCLC. Ann. Oncol. 15(3), 410-418 (2004).
54. Kakolyris S, Tsiafaki X, Agelidou A et al. Preliminary results of a multicenter randomized Phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 21, 296a (2002) (Abstract 1182).
55. Kosmas C, Tsavaris N, Kalofonos HP. Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent Phase II studies. Med. Sci. Monit. 8(6), PI58-PI63 (2002).
56. Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM, Whang-Peng J. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am. J. Clin. Oncol. 25(5), 509-512 (2002).
57. Niho S, Kubota Y, Goto K et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a Phase I/II trial. Cancer Chemother. Pharmacol. 52(1), 19-24 (2003).
58. Takeda K, Negoro S, Tamura T et al. Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): results of a JCOG randomized trial (JCOG0104). J. Clin. Oncol. 22(Suppl. 14), 625s (2004) (Abstract 7034).
59. Kouroussis C, Mavroudis D, Kakolyris S et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 44(3), 363-368 (2004).
60. Pectasides D, Farmakis D, Pectasides M et al. Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): a randomized Phase II trial. J. Clin. Oncol. 22(Suppl. 14), 625s (2004) (Abstract 7033).
61. Font A, Sanchez JM, Taron M et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest. New Drugs 21(4), 435-443 (2003 ).
62. Frasci G, Comella P, Thomas R et al. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A Phase I study. Cancer Chemother. Pharmacol. 53(1), 25-32 (2004).
63. Grossi F, Belvedere O, Rossetto C et al. Irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC): an Alpe Adria Thoracic Oncology Multidisciplinary group Phase II study (ATOM 007). J. Clin. Oncol. 22(Suppl. 14), 706S (2004) (Abstract 7363).
64. Keresztes RS, Socinski MA, Bonomi P, Chen A, Hart L, Lilenbaum RC. Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 22(Suppl. 14), 650S (2004) (Abstract 7137).
65. Ziotopoulos P, Chandrinos V, Samaras N et al. A Phase II study of docetaxel plus irinotecan (DOCIRI) in chemo-naive patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 22(Suppl. 14), 682S (2004) (Abstract 7267).
66. Ramalingam S, Dobbs TW, Coke DE, Wojtowicz-Praga S, Belani CP. Weekly docetaxel and irinotecan for patients with advanced non-small cell lung cancer (NSCLC): results of a multi-center, Phase II study. J. Clin. Oncol. 22(Suppl. 14), 690S (2004) (Abstract 7298).
67. Page RD, Smith FP, Geils GF et al. Prospective multi-center Phase II trial of docetaxel and vinorelbine with filgrastim support in subjects with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 22(Suppl. 14), 650S (2004) (Abstract 7138).
68. Pectasides D, Aspropotamitis A, Halikia A et al. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a Phase II study. J. Clin. Oncol. 17(12), 3816-3821 (1999).
69. Pectasides D, Visvikis A, Kouloubinis A et al. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a Phase II study. Eur. J. Cancer 38(9 , 1194-1200 (2002).
70. Kosmas C, Tsavaris NB, Makatsoris T et al. A Phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. Int. J. Cancer 98(1), 141-147 (2002).
71. Bessho A, Takata I, Shinkai T et al. A triplet chemotherapy with cisplatin, docetaxel and irinotecan in patients with Stage IIIB/IV non-small-cell lung cancer (NSCLC): a Phase I/II study of Okayama Lung Cancer Study Group (OLCSG). Proc. Am. Soc. Clin. Oncol. 22, 660 (2003) (Abstract 2654).
72. Perol M, Lena H, Thomas P et al. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with Stage IV non-small-cell lung cancer: GFPC 97.01 study. Ann. Oncol. 13(5), 742-747 (2002).
73. Yamamoto N, Fukuoka M, Negoro SI et al. Randomised Phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br. J. Cancer 90(1), 87-92 (2004).
74. Rigas JR, Carey M, Cole B et al. Multicenter Web-based Phase III study to test the survival equivalence of non-platinum-based (NPB) vs. platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): the Dartmouth NPB Chemotherapy Trial (D0112). J. Clin. Oncol. 22(Suppl. 14), 634s (2004) (Abstract 7071).
75. Langer CJ, Vangel M, Schiller J et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70). Proc. Am. Soc. Clin. Oncol. 22, 639 (2003) (Abstract 2571).
76. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Co-operative Oncology Group 5592, a randomized trial. J. Natl Cancer Inst. 94(3), 173-181 (2002).
77. Fossella FV, Belani CP, Group TS. Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC): analyses in elderly patients. Proc. Am. Soc. Clin. Oncol. 22, 629 (2003) (Abstract 2528).
78. Minami H, Ohe Y, Niho S et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin. Oncol. 22(14), 2901-2908 (2004).
79. Ten Tije AJ, Verweij J, Carducci MA, Rogers T, Dawkins FW, Baker SD. Prospective evaluation of the pharmacokinetic (PK) and toxicity profile of docetaxel in the elderly. J. Clin. Oncol. 22(Suppl. 14 , 739s (2004) (Abstract 8043).
80. Sweeney CJ, Zhu J, Sandler AB et al. Outcome of patients with a performance status of 2 in Eastern Co-operative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92(10), 2639-2647 (2001).
81. Sandbach JF, Weissman C, Brooker R, Ilegbodu D, Asmar L. A Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age <65 and performance status 2. J. Clin. Oncol. 22(Suppl. 14), 646s (2004) (Abstract 7122).
82. Lilenbaum RC, Rubin M, Samuel J et al. A Phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 22(Suppl. 14), 630s (2004) (Abstract 7057).
83. Hesketh PJ, Chansky K, Lau DH, Crowley J, Gandara DR, Group SO. Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: a SWOG Phase II trial (S0027). J. Clin. Oncol. 22(Suppl. 14), 630s (2004) (Abstract 7056).
84. Hainsworth JD, Erland JB, Barton JH et al. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network Phase II trial. Clin. Lung Cancer 5(1), 33-38 (2003).
85. Kim ES, Mauer AM, Tran HT et al. A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc. Am. Soc. Clin. Oncol. 22, 642 (2003) (Abstract 2581).
86. Fandi A, Gatzemeier U, Smith P, Averbuch S, Manegold C. Final data from a pilot trial of gefitinib (ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): safety and pharmacokinetics. Proc. Am. Soc. Clin. Oncol. 22, 655 (2003) (Abstract 2635).
87. Rixe O, Lemarie E, Chomy F et al. Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell-lung cancer (NSCLC): clinical results and biological monitoring. Proc. Am. Soc. Clin. Oncol. 22, 661 (2003) (Abstract 2659).
88. Kimura T, Mahaffey CM, Pryde BJ et al. Apoptotic effects of the docetaxelOSI-774 combination in non-small cell lung carcinoma (NSCLC) cells. J. Clin. Oncol. 22(Suppl. 14), 652s (2004) (Abstract 7143).
89. Fanucchi MP, Belt RJ, Fossella FV et al. Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): preliminary results. J. Clin. Oncol. 22(Suppl. 14), 643s (2004) (Abstract 7107).
90. Robert F, Busby E, Marques MB, Reynolds RE, Carey DE, Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer 42(2), 237-245 (2003).
91. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res. 10(12 Pt 2), 4270S-4275S (2004).
92. Herbst RS, Frankel SR. Oblimersen sodium (Genasense Bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin. Cancer Res. 10(12 Pt 2), 4245S-4248S (2004).
93. Ross HJ, Rudin CM, Hart LL et al. Randomized Phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 22(Suppl. 14), 626S (2004) (Abstract 7039).
94. Nugent FW, Graziano S, Levitan N et al. Docetaxel and COX-2 inhibition with celecoxib in relapsed/refractory non-small cell lung cancer (NSCLC): promising progression-free survival in a Phase II study. Proc. Am. Soc. Clin. Oncol. 22, 671 (2003) (Abstract 2697).
95. Chaplen RA, Kalemkerian GP, Wozniak A et al. Celecoxib (CEL) and weekly docetaxel (DOC) in elderly or PS2 patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 22(Suppl. 14), 641S (2004) (Abstract 7102).
96. Gadgeel SM, Thatai L, Kraut M et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. Proc. Am. Soc. Clin. Oncol. 22, 684 (2003) (Abstract 2749).
97. Winton TL, Livingston R, Johnson D et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected Stage 1B and II non-small cell lung cancer (NSCLC) Intergroup JBR.10. J. Clin. Oncol. 22(Suppl. 14), 621S (2004) (Abstract 7018).
98. Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol. 9633. J. Clin. Oncol. 22(Suppl. 14), 621S (2004) (Abstract 7019).